Optical Biometry Derived Axial Length Measurements Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema.
Details
Serval ID
serval:BIB_0FBA462D5C79
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Optical Biometry Derived Axial Length Measurements Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema.
Journal
Seminars in ophthalmology
ISSN
1744-5205 (Electronic)
ISSN-L
0882-0538
Publication state
Published
Issued date
2018
Peer-reviewed
Oui
Volume
33
Number
4
Pages
488-491
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
To evaluate axial length (AL) alterations in patients with macular disease over the course of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment.
In this prospective, comparative study, 33 patients with macular edema underwent unilaterally intravitreal anti-VEGF therapy and were followed for two months; the contralateral eyes were considered as controls. Central retinal thickness (CRT) was measured with spectral-domain optical coherence tomography and AL with an IOL-Master optical biometer.
CRT of the treated eyes decreased by 35.33 ± 65.59 μm (range, -222.00-67 μm), while AL increased by 0.008 ± 0.062 mm (range, -0.11-0.18 mm). CRT of the control group decreased by 9.82 ± 65.40 μm (range, -203-182 μm), and AL increased by 0.011 ± 0.129 mm (range, -0.20-0.67 mm). No significant correlation was detected between CRT and AL parameters (rhos=0.026, P=0.882).
Anti-VEGF administration has no significant impact on optical biometry-derived AL measurements.
In this prospective, comparative study, 33 patients with macular edema underwent unilaterally intravitreal anti-VEGF therapy and were followed for two months; the contralateral eyes were considered as controls. Central retinal thickness (CRT) was measured with spectral-domain optical coherence tomography and AL with an IOL-Master optical biometer.
CRT of the treated eyes decreased by 35.33 ± 65.59 μm (range, -222.00-67 μm), while AL increased by 0.008 ± 0.062 mm (range, -0.11-0.18 mm). CRT of the control group decreased by 9.82 ± 65.40 μm (range, -203-182 μm), and AL increased by 0.011 ± 0.129 mm (range, -0.20-0.67 mm). No significant correlation was detected between CRT and AL parameters (rhos=0.026, P=0.882).
Anti-VEGF administration has no significant impact on optical biometry-derived AL measurements.
Keywords
Aged, Angiogenesis Inhibitors/administration & dosage, Axial Length, Eye/diagnostic imaging, Biometry/methods, Female, Fluorescein Angiography, Fundus Oculi, Humans, Intravitreal Injections, Macula Lutea/pathology, Macular Edema/diagnosis, Macular Edema/drug therapy, Macular Edema/physiopathology, Male, Prospective Studies, Ranibizumab/administration & dosage, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A/antagonists & inhibitors, Visual Acuity, Anti-vascular endothelial growth factor, IOL Master biometry, axial length, central retinal thickness, macular edema
Pubmed
Web of science
Create date
28/04/2017 9:10
Last modification date
20/08/2019 12:36
Usage data
